Genentech, Roche halt enrollment in trial of Avastin
Following the sudden death of four patients for reasons unrelated to cancer, Genentech and its majority stakeholder Roche decided to ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.